The World Hypertension Market 2005-2010

Questions: Discounts, Updates etc.

Pages: 185

Price (Single): £1,799

Price (Departmental): £3,599

Price (Company): £5,399

Publication Date: 2005-11-03

Order Online Now

Name:
Email:
Company Name:
Telephone:
Licence Type:
Payment Method:

People that purchased this report also purchased:

Contact LeadDiscovery

If you have questions about this report
To find out if you qualify for a discount
Want a more up to date version
Can't find a report that meets your needs

Search all reports

The world hypertension market generated over $25 billion in 2004, with steady growth from the previous year. In this report, visiongain forecasts that revenues in the world hypertension market will grow to nearly $30 billion per year by 2010.

This market report examines the prospects of the world hypertension market from 2005-2010. This market is one of the largest and most important in the pharmaceutical industry. Furthermore, the treatment of hypertension is a central part of cardiovascular healthcare - itself at the forefront of public health.

This report examines the hypertension market critically through a comprehensive review of available information, including that from commercial databases, pipeline reports, academic research and consultation with international experts. Visiongain provides forecasting, SWOT analysis and the assessment of unmet needs to provide comprehensive financial forecasts, in-depth analyses and informed opinion.

In particular, this report concentrates on the following important issues:

The current state of the world market for drugs to treat hypertension
Drivers and opportunities in the hypertension market
Restraints and threats in the hypertension market
How the overall hypertension market is likely to grow between 2005-2010
Prospects for the current market leading drugs between 2005-2010
The potential for generics manufacturers to penetrate this market further
A breakdown of the world hypertension market into the principal geographical markets, with estimates of potential treatment populations and forecasted revenues in 2010
A discussion of unmet needs in the world hypertension market, with contributed opinions from experts
Detailed information on pipeline products and line extensions in this market

Why You Should Buy This Report

To receive a comprehensive analysis of the prospects of the world hypertension market from 2004-2010
To find out predicted revenues, growth rates and market shares for all the leading antihypertensive drugs from 2005-2010
To determine the forces that influence the hypertension market, especially:
- Competitive characteristics
- Drivers and restraints
- Strengths, weaknesses, opportunities and threats
- Unmet needs according to world experts, with gaps in the market exposed
To find out the prospects for antihypertensive drugs in the leading geographical markets:
- Potential treatment populations
- Potential 2010 revenues in the leading 7 markets
- Potential for growth of the hypertension market in other regions
To find out about pipeline developments for treating hypertension, as well as recent product launches

1. Executive Summary - Hypertension is a Dangerous Medical Condition and is a Serious Cause of Mortality Worldwide

2. Introduction to Hypertension
- 2.1 An Overview of Hypertension
- 2.2 Symptoms of Hypertension and Diagnosis of the Condition
- 2.3 Causes of Hypertension
- 2.4 Primary Hypertension
- 2.5 Secondary Hypertension
- 2.6 Pulmonary Hypertension
- 2.7 Epidemiology of Hypertension
- 2.8 Links with Other Disorders
- 2.9 The Treatment of Hypertension
  - 2.9.1 Countering Hypertension Through Changes in Diet and Lifestyle - A First Line of Attack
  - 2.9.2 Treatment Targets and the Selection of Drugs
  - 2.9.3 Beta Blockers
  - 2.9.4 Angiotensin Converting Enzyme (ACE) Inhibitors
  - 2.9.5 Calcium-Channel Blockers
  - 2.9.6 Angiotensin II Blockers
  - 2.9.7 Alpha Blockers
  - 2.9.8 Diuretics
  - 2.9.9 Other Drugs
  - 2.9.10 Treatment of Pulmonary Hypertension
- 2.10 The Prospects for Patients
3. The World Hypertension Market, 2004-2010
- 3.1 Growing Demand and Shifting Internal Dynamics in the World Antihypertensive Market, 2004-2010
- 3.2 Novartis to Become the Leading Company in the 2010 Hypertension Market
- 3.3 Angiotensin II Blockers to Continue Their Domination of the Antihypertensive Market, 2005-2010
- 3.4 Other Classes of Antihypertensive Drug Display High Revenues during 2004-2010
- 3.5 Calcium Channel Blockers - Declining Revenues due to Competition
- 3.6 Angiotensin Converting Enzyme (ACE) Inhibitors - Will This Class Be Superseded by the Angiotensin II Blockers?
- 3.7 Beta-Blockers - Carving a Secure Niche in a Highly Competitive Market
- 3.8 Alpha Blockers Will Maintain a Respected Position in the Hypertension Market
- 3.9 Increasing Potential for Blockbuster Revenues During 2004-2010
- 3.10 Competition in the Antihypertensive Market to Become Increasingly Intense
- 3.11 Monotherapy or Combination Therapy?
- 3.12 Diuretic Agents Retain Importance
4. The World Market for Angiotensin II Blockers, 2004-2010
- 4.1 Angiotensin II Blockers - Strong Growth Leads to Continuing Predominance in the Market
  - 4.1.1 The Angiotensin II Blockers Will Benefit From More Secure Patent Protection Than The Other Classes of Antihypertensives
  - 4.1.2 Other Advantages of Angiotensin II Blockers That Confer Important Benefits in the Market
- 4.2 Diovan to Take Market Leadership from Norvasc by 2010
  - 4.2.1 Diovan Benefits from Further Clinical Studies
- 4.3 Cozaar/Hyzaar - High Revenues with Continued Growth
  - 4.3.1 Further Developments for Cozaar/Hyzaar
- 4.4 Blopress - Another Strong Performer
  - 4.4.1 Additional FDA Approval for Blopress
- 4.5 Sanofi-Aventis' Aprovel/Avapro to Maintain Steady Growth
  - 4.5.1 Avaprovel/Avapro Benefits from Continuing Development
- 4.6 Bristol-Myers Squibb's Avapro/Avalide Will Also Benefit from This Growing Market
- 4.7 Atacand - Reversion of Licensing Rights to Original Manufacturer
- 4.8 Boehringer Ingelheim's Micardis Will Achieve Blockbuster Revenues By 2010
  - 4.8.1 Micardis Shows Potential Metabolic Benefits
  - 4.8.2 Micardis Benefits from Further Clinical Studies
- 4.9 Astellas Pharmaceutical's Micardis Will Achieve Very High Growth Over The Forecast Period
  - 4.9.1 Further Clinical Studies May Confer a Market Advantage to Astellas' Micardis
- 4.10 Provas/Miten - Only Modest Success is Predicted for This Drug
- 4.11 Benicar's Revenue Growth Set to Continue Steadily
  - 4.11.1 Further Licensing Agreements for Benicar
  - 4.11.2 Promising Results from Further Clinical Study
- 4.12 The Angiotensin II Blockers: Summary and Conclusions
5. The World Market for Calcium Channel Blockers, 2004-2010
- 5.1 Increased Competition Will Lower Revenues
- 5.2 Norvasc - 2004 Market Leader Set to Lose Dominance to Leading Angiotensin II Blockers
  - 5.2.1 Norvasc Benefits from Further Clinical Testing
  - 5.2.2 Active Ingredient in Norvasc Combined with that of Lipitor to Form Dual Action Cardiovascular Drug
- 5.3 Adelat - The Second Largest Calcium Blocker, But Significantly Behind Norvasc
- 5.4 Plendil - Declining Revenues Predicted
- 5.5 Coniel Will Sustain Revenues
- 5.6 Herbesser Faces Slight Decline in Revenues
  - 5.6.1 The Outcome of Further Clinical Studies on Herbesser
- 5.7 Lercanidipine - Optimism Due to Further Launches and Product Development
  - 5.7.1 Lercandipine to Be Released in More Countries
  - 5.7.2 Lercandipine Receives Continuing Product Development
- 5.8 Perpidine/Perpidine LA - Revenue Decline Predicted
- 5.9 Calslot Will Show Moderate Revenue Growth
- 5.10 Lower Revenue Calcium Blockers: Nivadil, Verelan PM and Cardizem LA
  - 5.10.1 Cardizem LA Is Undergoing Further Development
- 5.11 The Calcium Blockers: Summary and Conclusions
6. The World Market for Angiotensin Converting Enzyme (ACE) Inhibitors, 2004-2010
- 6.1 How Well Will The ACE Inhibitors Resist Competition From The Angiotensin II Blockers?
  - 6.1.1 ACE Inhibitors Will Retain Prominence in The Market
- 6.2 Delix/Tritace Will Lose Predominance In This Class
  - 6.2.1 Licensing Agreements for International Distribution
  - 6.2.2 Further Clinical Studies and Life Cycle Management to Confer Benefits to Delix/Tritace
- 6.3 Lotrel Will Become The ACE Inhibitor With The Highest Revenues
- 6.4 Vasotec/Vaseretic - This Older Drug Will Face Decline
  - 6.4.1 Additional Clinical Studies and Product Development to Benefit Vasotec
- 6.5 Accupril/Accuretic - Revenues Set To Fall
  - 6.5.1 Accupril/Accuretic Faces Patent Challenges
- 6.6 Zestril - Expiry of Patent Leads to Continuing Decline
- 6.7 Monopril Faces a Steep Decline In Revenue
- 6.8 Tanatril Is Likely to Struggle to Maintain Revenues
- 6.9 ACE Inhibitors With Lower Revenues: Acecol and Longes
- 6.10 The ACE inhibitors: Summary and Conclusions
7. The World Market for Beta-Blockers, 2004-2010
- 7.1 Beta Blockers Will Retain Their Niche in a Highly Competitive Market
  - 7.1.1 Uses and Limitations of Beta Blockers That Affect Their Position In The Market
- 7.2 Toprol-XL/Seloken Will Become the Second Most Important Beta Blocker
  - 7.2.1 Toprol-XL Faces Patent Challenges
- 7.3 Coreg Is Set to Lead the Beta Blocker Class
  - 7.3.1 Coreg May Benefit From Further Clinical Studies
- 7.4 Maintate Faces Declining Revenues
- 7.5 The Beta Blockers: Summary and Conclusions
8. The World Market for Alpha Blockers, 2004-2010
- 8.1 Alpha blockers Will Defend Their Position in the Hypertension Market
  - 8.1.1 Alpha Blockers Are Also Used to Treat BPH
  - 8.1.2 Limitations On The Use of Alpha Blockers Influence Their Performance in The Market
- 8.2 Cardura Will Dominate the Alpha Blocker Class
- 8.3 Catapresan Will Be Second Largest Drug In Its Class
- 8.4 Ebrantil Will Have Lowest Market Share in Class
- 8.5 The Alpha Blockers: Summary and Conclusions
9. An Analysis of Factors That Influence the Hypertension Market
- 9.1 SWOT Analysis of the Hypertension Market
- 9.2 An Expanding Patient Population Constitutes the Principal Driver in the Hypertension Market
- 9.3 The Hypertension Market Has Opportunities for Continuing Growth
- 9.4 Changes in Blood Pressure Treatment Guidelines - Can Both Patients and Drug Companies Benefit?
- 9.5 Advances in Technology Are Likely to Bring Benefits to the Market
- 9.6 The Principal Restraints in the Hypertension Market
- 9.7 To What Extent is the Hypertension Market Threatened by Generic Substitutes?
- 9.8 What Unmet Market Needs Exist in the Hypertension Market? - Experts Provide Their Views
  - 9.8.1 Resistant Hypertension Constitutes a Major Limitation of Present Treatments
  - 9.8.2 Important Patient Sub-Populations: Potential For Companies To Increase Market Leverage Through Product Differentiation
- 9.9 Comparative Studies - A Two Edged Sword
10. A Geographical Breakdown of the World Hypertension Market
- 10.1 The US Will Lead a High Revenue Global Market in 2010
- 10.2 The Prevalence of Hypertension Worldwide - Many Hypertensive People Currently Untreated or Under-treated
- 10.3 Conclusions: There is An Urgent Requirement To Expand the Treatment of Hypertension on a Global Scale
11. Pipeline Drugs for Hypertension
- 11.1 Agents in Phase II of Clinical Development
  - 11.1.1 Darusentan From Myogen
  - 11.1.2 MC-4232 From Medicure
  - 11.1.3 MC-1 From Medicure
  - 11.1.4 MC-4262 From Medicure
  - 11.1.5 Ventavis From CoTherix For More Specialised Indication
- 11.2 Agents in Phase III of Clinical Development
  - 11.2.1 Aliskiren (SPP100) From Novartis
  - 11.2.2 Ambrisentan From Myogen
  - 11.2.3 Thelin From Encysive
  - 11.2.4 PW2101 From Penwest
  - 11.2.5 (S)-amlodipine From Sepracor
- 11.3 Recently Approved Agents for Treating Hypertension
  - 11.3.1 Revatio From Pfizer
  - 11.3.2 Nebivolol From Mylan
  - 11.3.3 Ventavis From CoTherix
  - 11.3.4 Ventavis Monopril-HCT From Ranbaxy
  - 11.3.5 Hydrochlorothiazide From Ivax
  - 11.3.6 Other Recently Approved Agents for Hypertension
- 11.4 An Overall Assessment of Pipeline Developments for the Hypertension Market
12. Conclusions: Hypertension Constitutes a Large Drugs Market With Scope For Expansion Worldwide
- 12.1 Hypertension is a Serious, Growing Problem Worldwide
- 12.2 Hypertension Constitutes a High Revenue Market with Continuing Growth Potential
- 12.3 Hypertension Drugs will Achieve High Revenues in all the Major Geographical Markets from 2005-2010
- 12.4 The Pipeline for Hypertension Drugs is Strong
- 12.5 Continuing Public and Private Sector Investment is Required

TABLES

Table 2.1, Categories for Blood Pressure Levels in Adults

Table 2.2, Leading Beta-Blockers to Treat Hypertension, 2004

Table 2.3, Leading ACE Inhibitors to Treat Hypertension

Table 2.4, Leading Calcium Channel Blockers to Treat Hypertension

Table 2.5, Leading Angiotensin II Blockers to Treat Hypertension

Table 2.6, Leading Alpha Blockers to Treat Hypertension, 2004

Table 3.1, Blockbuster Drugs in the World Hypertension Market, 2004

Table 3.2, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2004-2010

Table 3.3, World Market Revenue ($m) and Market Share (%) for Leading Hypertension Drugs by Class, 2010

Table 3.4, Blockbuster Drugs in the World Hypertension Market, 2010

Table 4.1, World Revenues ($m) for Angiotensin II Blockers, 2004-2010

Table 4.2, Patent Expiry for Angiotensin II Blockers, 2005

Table 4.3, World Market Shares (%) for Angiotensin II Blockers, 2004 and 2010

Table 5.1, World Revenues ($m) for Calcium Channel Blockers, 2004-2010

Table 5.2, Patent Expiry for Calcium Channel Blockers to Treat Hypertension

Table 5.3, World Market Shares (%) for Calcium Blockers, 2004 and 2010

Table 6.1, World Revenues ($m) for ACE Inhibitors, 2004-2010

Table 6.2, Patent Expiry for ACE Inhibitors to Treat Hypertension

Table 6.3, World Market Shares (%) for ACE Inhibitors, 2004 and 2010

Table 7.1, World Revenues ($m) for Beta-Blockers, 2004-2010

Table 7.2, Patent Expiry for Beta-Blockers to Treat Hypertension

Table 7.3, World Market Shares (%) for Beta Blockers, 2004 and 2010

Table 8.1, World Revenues ($m) for Alpha Blockers, 2004-2010

Table 8.2, Patent Expiry for Alpha Blockers to Treat Hypertension

Table 8.3, World Market Shares (%) for Alpha Blockers, 2004 and 2010

Table 9.1, Leading Antihypertensive Drugs That Face The Greatest Threat From Generic Competition, 2005

Table 10.1, Estimated Hypertensive Patient Populations by Country, 2004

Table 10.2, Estimated Revenues ($m) For Hypertension Drugs by Country and (%) World Market Shares, 2004 and 2010

Table 12.1, World Market Revenue ($m) and Market Share (%) for Leading Hypertension Drugs by Class, 2010

Table 12.2, Revenues ($m) For Hypertension Drugs by Country, 2010

FIGURES

Figure 3.1, World Revenues ($m) for the Classes of Leading Drugs to Treat Hypertension, 2004-2010

Figure 3.2, World Market Share (%) for Hypertension by Class, 2004

Figure 3.3, World Market Share (%) for Hypertension by Class, 2010

Figure 3.4, Market Share (%) for Leading Hypertension Drugs by Company, 2004

Figure 3.5, Market Share (%) for Leading Hypertension Drugs by Company, 2010

Figure 3.6, Changes ($m) in World Revenues for the Classes of Hypertension Drugs, 2004-2010

Figure 3.7, Changes (%) in World Revenues for the Classes of Hypertension Drugs, 2004-2010

Figure 4.1, World Revenues ($m) for All Angiotensin II Blockers, 2004-2010

Figure 4.10, World Micardis (Boehringer Ingelheim) Revenues ($m), 2004-2010

Figure 4.11, World Micardis (Astellas Pharma) Revenues ($m), 2004-2010

Figure 4.12, World Provas/Miten Revenues ($m), 2004-2010

Figure 4.13, World Benicar Revenues ($m), 2004-2010

Figure 4.2, World Revenues ($m) for the Angiotensin II Blockers by drug, 2004-2010

Figure 4.3, World Market Share (%) for Angiotensin II Blockers, 2004

Figure 4.4, World Market Share (%) for the Angiotensin II Blockers, 2010

Figure 4.5, World Diovan/Co-Diovan Revenues ($m), 2004-2010

Figure 4.6, World Cozaar/Hyzaar Revenues ($m), 2004-2010

Figure 4.7, World Blopress Revenues ($m), 2004-2010

Figure 4.8, World Aprovel/Avapro Revenues ($m), 2004-2010

Figure 4.9, World Avapro/Avalide Revenues ($m), 2004-2010

Figure 5.1, World Revenue ($m) for Calcium Channel Blockers, 2004-2010

Figure 5.10, World Lercandidipine Revenues ($m), 2004-2010

Figure 5.11, World Perpidine/Perpidine LA Revenues ($m), 2004-2010

Figure 5.12, World Calslot Revenues ($m), 2004-2010

Figure 5.13, World Nivadil Revenues ($m), 2004-2010

Figure 5.14, World Verelan PM Revenues ($m), 2004-2010

Figure 5.15, Cardizem LA Revenues ($m), 2004-2010

Figure 5.2, World Revenues ($m) for Calcium Channel Blockers, 2010

Figure 5.3, World Market Share (%) for Calcium Channel Blockers, 2004

Figure 5.4, World Market Share (%) for Calcium Channel Blockers, 2010

Figure 5.5, World Norvasc Revenues ($m), 2004-2010

Figure 5.6, World Adalat Revenues ($m), 2004-2010

Figure 5.7, World Plendil Revenues ($m), 2004-2010

Figure 5.8, World Coniel Revenues ($m), 2004-2010

Figure 5.9, World Herbesser Revenues ($m), 2004-2010

Figure 6.1, World Revenue ($m) for All ACE Inhibitors, 2004-2010

Figure 6.10, World Monopril Revenues ($m), 2004-2010

Figure 6.11, World Tanatril Revenues ($m), 2004-2010

Figure 6.12, World Acecol Revenues ($m), 2004-2010

Figure 6.13, World Longes Revenues ($m), 2004-2010

Figure 6.2a, World Revenues ($m) for the ACE Inhibitors, 2004-2010

Figure 6.2b, World Revenues ($m) for Monopril, Tanatril, Acecol & Longes, 2004-2010

Figure 6.3, World Market Share (%) for ACE Inhibitors, 2004

Figure 6.4, World Market Share (%) for ACE Inhibitors, 2010

Figure 6.5, World Delix/Tritace Revenues ($m), 2004-2010

Figure 6.6, World Lotrel Revenues ($m), 2004-2010

Figure 6.7, World Vasotec/Vaseretic Revenues ($m), 2004-2010

Figure 6.8, World Accupril/Accuretic Revenues ($m), 2004-2010

Figure 6.9, World Zestril Revenues ($m), 2004-2010

Figure 7.1, World Revenues ($m) for the Beta Blockers: Total for Class, 2004-2010

Figure 7.2, World Revenues ($m) for the Beta Blockers, 2004-2010

Figure 7.3, World Market Share (%) for Beta-Blockers, 2004

Figure 7.4, World Market Share (%) for Beta-Blockers, 2010

Figure 7.5, World Toprol-XL/Seloken Revenues ($m), 2004-2010

Figure 7.6, World Coreg Revenues ($m), 2004-2010

Figure 7.7, World Maintate Revenues ($m), 2004-2010

Figure 8.1, World Revenues ($m) for the Alpha Blockers: Total for Market, 2004-2010

Figure 8.2, World Revenues ($m) for the Alpha Blockers, 2004-2010

Figure 8.3, World Market Share (%) for Alpha Blockers, 2004

Figure 8.4, World Market Share (%) for Alpha Blockers, 2010

Figure 8.5, World Cardura Revenues ($m), 2004-2010

Figure 8.6, Catapresan Revenues ($m), 2004-2010

Figure 8.7, Ebrantil Revenues ($m), 2004-2010

Figure 9.1, A SWOT Chart for the Hypertension Market, 2005-2010

Figure 10.1, Estimated Hypertensive Populations by Country

Figure 10.2, Revenues ($m) for Hypertension Drugs by Country, 2010

Other users found this report page using the following search terms: hypertension antihypertensive blood pressure ace arb market hypertension antihypertensive share drugs world ace expiry patent drug

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

The World Hypertension Market 2005-2010

Credit Card Details

Invoice Details

Table of Contents